Plasma glycated albumin level and atherosclerosis: Results from the Kyushu and Okinawa Population Study (KOPS)

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 2066-2072

  Furusyo, Norihiro ^a,b   Koga, Tsunehisa ^a   Ai, Masumi ^c,d   Otokozawa, Seiko ^c,e   Kohzuma, Takuji ^f   Ikezaki, Hiroaki ^b   Schaefer, Ernst J ^c   Hayashi, Jun ^a,b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e SAPPORO MEDICAL UNIVERSITY   (Japan)

^f ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

C reactive protein; Glycated albumin; Intima media thickness

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

C-REACTIVE PROTEIN; GLYCATED ALBUMIN; INTIMA-MEDIA THICKNESS;

ADULT; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOSYLATION; HUMANS; JAPAN; MALE; MIDDLE AGED; OBESITY; POPULATION SURVEILLANCE; RISK FACTORS; SERUM ALBUMIN;

EID: 84883268660     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.05.045     Document Type: Article

References (36)

1. D.M. Nathan Long-term complication of diabetes mellitus N Engl J Med 328 1993 1676 1685
2. W.B. Kannel, and D.L. McGee Diabetes and cardiovascular disease: the Framingham study JAMA 241 1979 2053 2058
3. L.M. Delahanty, and B.N. Halford The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial Diabetes Care 16 1993 1453 1458
4. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
5. Y. Ohkubo, H. Kishikawa, and E. Araki Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study Diabetes Res Clin Pract 28 1995 103 117
6. H.C. Gerstein, M.C. Riddle, and D.M. Kendall Feeney P; ACCORD Study Group 2007 Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Am J Cardiol 99 2007 34i 43i
7. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
8. M.S. Kirkman, M. McCarren, J. Shah, W. Duckworth, C. Abraira, and VADT Study Group The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: the VA cooperative study in diabetes J Diabetes Complications 20 2006 75 80
9. Y. Sawayama, C. Shimizu, and N. Maeda Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST) J Am Coll Cardiol 39 2002 610 616
10. V. Nambi, L. Chambless, and A.R. Folsom Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study J Am Coll Cardiol 55 2010 1600 1607
11. T.J. Anderson, F. Charbonneau, and L.M. Title Microvascular function predicts cardiovascular events in primary prevention: Long-term results from the Firefighters and Their Endothelium (FATE) study Circulation 123 2011 163 169
12. Y. Yamasaki, M. Kodama, and H. Nishizawa Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease Diabetes Care 23 2000 1310 1315
13. M. Koyasu, H. Ishii, and M. Watarai Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease Clin Ther 32 2010 1610 1617
14. T. Bobbert, K. Mai, A. Fischer-Rosinsky, and A.F. Pfeiffer Spranger J 2010 A1C is associated with intima-media thickness in individuals with normal glucose tolerance Diabetes Care 33 2010 203 204
15. S. Verma, C.H. Wang, and S.H. Li A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis Circulation 106 2001 913 919
16. J.L. Anderson, J.F. Carlquist, J.B. Muhlestein, B.D. Horne, and S.P. Elmer Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction J Am Coll Cardiol 32 1998 35 41
17. A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, and P. Ridker C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 2001 327 334
18. F.B. Hu, J.B. Meigs, T.Y. Li, N. Rifai, and J.E. Manson Inflammatory markers and risk of developing type 2 diabetes in women Diabetes 53 2004 693 700
19. C.E. Guthrow, M.A. Morris, J.F. Day, S.R. Thorpe, and J.W. Baynes Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus Proc Natl Acad Sci U S A 76 1979 4258 4261
20. S. Takahashi, H. Uchino, and T. Shimizu Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control Endocr J 54 2007 139 144
21. L.Y. Tsai, S.M. Tsai, M.N. Lin, and S.F. Liu Effect of hemoglobin variants (Hb J, Hb G, and Hb E) on HbA1c values as measured by cation-exchange HPLC (Diamat) Clin Chem 47 2001 756 758
22. M. Ai, S. Otokozawa, and E.J. Schaefer Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus Clin Chim Acta 406 2009 71 74
23. T. Kouzuma, T. Usami, M. Yamakoshi, M. Takahashi, and S. Imamura An enzymatic method for the measurement of glycated albumin in biological samples Clin Chim Acta 324 2001 61 71
24. K. Yoshiuchi, M. Matsuhisa, and N. Katakami Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes Endocr J 55 2008 503 507
25. T. Suwa, A. Ohta, and T. Matsui Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM) Endocr J 57 2010 135 140
26. L. Lu, L.J. Pu, and X.W. Xu Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus Clin Biochem 40 2007 810 816
27. N. Furusyo, T. Koga, and M. Ai Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS) Diabetologia 54 2011 3028 3036
28. H. Ohnishi, Y. Sawayama, N. Furusyo, S. Maeda, S. Tokunaga, and J. Hayashi Risk factors for and the prevalence of peripheral arterial disease and its relationship to carotid atherosclerosis: The Kyushu and Okinawa Population Study (KOPS) J Atheroscler Thromb 30 2010 751 758
29. M. Unno, N. Furusyo, H. Mukae, T. Koga, K. Eiraku, and J. Hayashi The utility of visceral fat level by bioelectrical impedance analysis in the screening of metabolic syndrome: the results of the Kyushu and Okinawa Population Study (KOPS) J Atheroscler Thromb Jan 31 2012 [Epub ahead of print]
30. M. Koga, J. Murai, H. Saito, M. Otsuki, and S. Kasayama Evaluation of glycated albumin/HBA1c ratio by stage of diabetic nephropathy Diabetol Int 2011 10.1007/s13340-011-0033-z
31. A. Geistanger, S. Arends, and C. Berding Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan, and Sweden Clin Chem 54 2008 1379 1385
32. D.M. Nathan, M.W. Steffes, W. Sun, G.P. Rynders, and J.M. Lachin Determining stability of stored samples retrospectively: the validation of glycated albumin Clin Chem 57 2011 286 290
33. E.J. Schaefer, M.C. Audelin, and J.R. McNamara Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease Am J Cardiol 88 2001 1129 1133
34. The Diabetes Epidemiology Collaborative analysis Of Diagnostic (DECOD) study group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria Lancet 354 1999 617 621
35. M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, and A. Sekikawa Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata diabetes study Diabetes Care 22 1999 920 924
36. J.L. Chiasson, R.G. Josse, and R. Gomis Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 2003 486 494